Wednesday November 1, 7:02 am Eastern Time
Press Release
SOURCE: InterMune Pharmaceuticals, Inc.
InterMune Announces Meeting to Discuss Clinical Advances in Idiopathic Pulmonary Fibrosis
BURLINGAME, Calif., Nov. 1 /PRNewswire/ -- InterMune (Nasdaq: ITMN - news) will host an analyst meeting for the investment community on Wednesday, November 1, 2000, from 4:15 p.m. to 6:30 p.m. (EST) to discuss clinical advances and medical education in idiopathic pulmonary fibrosis. Interested parties may access audio of the meeting either live or on a replay basis for one week following the meeting by visiting our website at www.intermune.com and clicking on the ``Investor Relations'' icon.
InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE® (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE®, please visit InterMune's web sites at www.intermune.com and www.actimmune.com, or send e-mail to ir@intermune.com.
SOURCE: InterMune Pharmaceuticals, Inc. |
